Bristol-Myers Squibb Co
BMY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$41.00 | Mmcvb | Zbghxpyjhd |
Bristol-Myers: R&D Update Highlights Mid-Range Drugs Important to Offsetting Patent Losses
Bristol-Myers hosted a research and development event on Sept.14 highlighting several mid-stage drugs that should enter pivotal studies over the next 18 months. While the heightened visibility increases our confidence in the firm's moat, we didn't see anything that materially changed our valuation outlook. We need to see the results of the pivotal studies to materially change our projections, as the early-stage data looks promising but still uncertain.